Registered title, quoted from ClinicalTrials.gov
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05495152, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Histologically proven squamous cell carcinoma.
Inclusion criterion 1
Patients with resectable cT1-4aN+M0 or T3-4aN0M0 disease and residue disease is found after neoadjuvant chemotherapy plus surgery or cT1-2N0M0 and pathologically proven T1-2N+M0 after upfront surgery.
Inclusion criterion 5
Patients with clinical stages T1-2N+M0 and receive upfront surgery.
Exclusion criterion 4
Patients with unresectable disease (bulky metastatic lymph nodes or T4b) and receive induction chemotherapy.
Exclusion criterion 5
ECOG performance status of 0 or 1.
Inclusion criterion 4
Patients with human immunodeficiency virus (HIV) infection.
Exclusion criterion 12
Pregnant or lactating women or women of childbearing potential.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05495152, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histologically proven squamous cell carcinoma.
- Tumours are located in the thoracic oesophagus.
- Age is between 18 years and 70 years.
- ECOG performance status of 0 or 1.
- Patients with resectable cT1-4aN+M0 or T3-4aN0M0 disease and residue disease is found after neoadjuvant chemotherapy plus surgery or cT1-2N0M0 and pathologically proven T1-2N+M0 after upfront surgery.
- No metastatic cervical lymph nodes.
- R0 resection is achieved by the minimally invasive esophagectomy (MIE) or open McKeown approach with total two-field lymph nodes dissection or three-field lymph nodes dissection.
- No prior therapy was administered against other cancers.
- Adequate bone marrow function: white blood cell count ≥ 4×109/L; absolute neutrophil count (ANC) ≥ 1.5×109/l; platelets ≥ 100×109/L; haemoglobin ≥ 9 g/dl.
- Adequate liver function: serum bilirubin ≤ 1.5 × upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.0 × ULN (ULN as per institutional standard).
- Adequate renal function: glomerular filtration rate ≥ 60 ml/min calculated using the Cockcroft-Gault formula.
- Normal thyroid function.
- Written consent is obtained.
Exclusion Criteria:
- Patients receive neoadjuvant chemoradiation therapy.
- Patients with pathological complete response (pCR).
- No. of lymph node dissection < 15.
- Patients with clinical stages T1-2N+M0 and receive upfront surgery.
- Patients with unresectable disease (bulky metastatic lymph nodes or T4b) and receive induction chemotherapy.
- Patients requiring systemic steroid medication.
- Patients with severe postoperative complications and not suitable for adjuvant therapy.
- Synchronous or metachronous (within 5 years) double cancers.
- Patients ever received immunotherapy.
- Active infection requiring systemic therapy.
- Patients ever received organ transplant or allogenic haemopoietic stem cell transplantation.
- Patients with human immunodeficiency virus (HIV) infection.
- Psychiatric disease.
- Pregnant or lactating women or women of childbearing potential.
- Hypersensitivity for Sintilimab.
Quoted from ClinicalTrials.gov, NCT05495152, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05495152, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.